ArticlePharmaceutics2021
Topical Nanoemulgel for the Treatment of Skin Cancer: Proof-of-Technology.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Nanoemulgels as Advanced Topical Drug Delivery Systems: Mechanistic Insights and Therapeutic Applications in Skin Disorders, Infections, Wound Healing, and Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Potent Anticancer, Antimicrobial, and Anti-Inflammatory Activities of Boswellia sacra Extracted Oil Nanoemulgel.BioMed research international · 2026Article
- Recent progress in topical and transdermal approaches for melanoma treatment.Drug delivery and translational research · 2025Review
- Quercetin Nano-formulations as a Potential Approach for Skin Cancer.Pharmaceutical nanotechnology · 2025Review
- Nanoemulsions in Skin Cancer Therapy: A Promising Frontier.Current pharmaceutical biotechnology · 2025Review
- Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery.Pharmaceutics · 2024Review
- Development of nanoemulgel of 5-Fluorouracil for skin melanoma using glycyrrhizin as a penetration enhancer.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Self-Nanoemulsion Intrigues the Gold Phytopharmaceutical Chrysin: In Vitro Assessment and Intrinsic Analgesic Effect.AAPS PharmSciTech · 2024Article
- Development and preclinical assessment of nanoemulgel loaded with phytoconstituents for the management of rheumatoid arthritis.Drug delivery and translational research · 2024Article
- Novel Therapeutic Hybrid Systems Using Hydrogels and Nanotechnology: A Focus on Nanoemulgels for the Treatment of Skin Diseases.Gels (Basel, Switzerland) · 2024Review
- Development of a Nanoemulgel for the Topical Application of Mupirocin.Pharmaceutics · 2023Article
- Topical Drug Delivery: Innovative Controlled Release Systems.Pharmaceutics · 2023Article
- Gel Formulations for Topical Treatment of Skin Cancer: A Review.Gels (Basel, Switzerland) · 2023Review
- The Science of Selecting Excipients for Dermal Self-Emulsifying Drug Delivery Systems.Pharmaceutics · 2023Review
- Nanoemulgel: A Novel Nano Carrier as a Tool for Topical Drug Delivery.Pharmaceutics · 2023Review
- Anti-inflammatory activities of flavonoid derivates.ADMET & DMPK · 2023Review
- Design-of-Experiments (DoE)-Assisted Fabrication of Quercetin-Loaded Nanoemulgel and Its Evaluation against Human Skin Cancer Cell Lines.Pharmaceutics · 2022Article
- Formulation-by-Design of Efinaconazole Spanlastic Nanovesicles for Transungual Delivery Using Statistical Risk Management and Multivariate Analytical Techniques.Pharmaceutics · 2022Article
- Adenosine Conjugated Docetaxel Nanoparticles-Proof of Concept Studies for Non-Small Cell Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Aerosol Delivery of Surfactant Liposomes for Management of Pulmonary Fibrosis: An Approach Supporting Pulmonary Mechanics.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The present study is a mechanistic validation of 'proof-of-technology' for the effective topical delivery of chrysin nanoemulgel for localized, efficient treatment of melanoma-affected skin.
backgroundCurrently available treatments for skin cancer are inefficient due to systemic side effects and poor transcutaneous permeation, thereby presenting a formidable challenge for the development of novel nanocarriers.
methodsWe opted for a novel approach and formulated a nanocomplex system composed of hydrophobic chrysin dissolved in a lipid mix, which was further nanoemulsified in Pluronic
resultsThis thermodynamically stable, self-emulsifying drug delivery system showed a mean droplet size of 156.9 nm, polydispersity index of 0.26, and viscosity of 9100 cps after dispersion in gel. Mechanical characterization using Texture Analyzer exhibited that the gel had a hardness of 487 g and adhesiveness of 500 g. Ex vivo permeation through rat abdominal skin revealed significant improvement in percutaneous absorption measured as flux, the apparent permeability coefficient, the steady-state diffusion coefficient, and drug deposition. In vitro cytotoxicity on A375 and SK-MEL-2 cell lines showed a significantly improved therapeutic effect, thus ensuring reduction in dose. The safety of the product was established through biocompatibility testing on the L929 cell line.
conclusionAqueous, gel-based, topical, nanoemulsified chrysin is a promising technology approach for effective localized transcutaneous delivery that will help reduce the frequency and overall dose usage and ultimately improve the therapeutic index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.